{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"}],"units":"Participants"}],"description":"Adverse Events (AEs) and Serious Adverse Events (SAEs) will be evaluated continuously throughout the study. Safety and tolerability will be assessed according to the NIH/NCI Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0).","groups":[{"description":"The investigational drug used in this study is pasireotide long acting release (LAR) 60 mg.\n\nPasireotide Long Acting Release (LAR): Pasireotide will be administered as an intramuscular injection at the beginning of every cycle which is defined as 28 days (+/- 3 days). Study treatment should begin within 14 days following enrollment into the study and continue until disease progression, unacceptable toxicity, or withdrawal of consent.","id":"OG000","title":"Pasireotide LAR Treatment"}],"paramType":"NUMBER","populationDescription":"All participants who received at least one dose of study drug","reportingStatus":"POSTED","timeFrame":"Up to 48 months","title":"Adverse Events Possibly Related to Study Treatment","type":"SECONDARY","unitOfMeasure":"events"}